LGND — Ligand Pharmaceuticals Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual cashflow statement for Ligand Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-2.98	57.1	-33.4	52.2	-4.03
Depreciation
Deferred Taxes
Non-Cash Items	61	31.4	33.3	-16.4	62.3
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-10.1	-52.2	65.7	-34.4	19.4
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	54.6	78.8	138	49.6	97
Capital Expenditures	-4.46	-8.76	-17.9	-64.3	-1.82
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	236	39.3	182	52.6	-142
Acquisition of Business
Sale of Business
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Sale of Intangible Assets
Change in Net Intangibles
Other Investing Cash Flow
Cash from Investing Activities	232	30.5	164	-11.7	-144
Financing Cash Flow Items	-3.81	11.9	-18.2	-5.5	-5.56
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-311	-138	-276	-59.9	97.1
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-24.3	-28.4	25.5	-22.1	49.4